Short answer
BridgeBio Pharma, Inc. (BBIO) filed an 8-K current report with the SEC on October 29, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Third-quarter results for period ended September 30, 2026, covering financial performance and recent business updates.
BridgeBio Pharma, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Third-quarter results for period ended September 30, 2026, covering financial performance and recent business updates
- Exhibit 99.1 contains the full earnings release, the primary source for detailed results and guidance
- Market focus: BridgeBio’s pipeline progress and cash position alongside quarterly operating performance
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $353.2M, including Attruby product revenue $253.2M, up $145.2M year over year
- Attruby adoption accelerating in treatment-naïve patients, strengthening commercial momentum in ATTR-CM
- Cash, equivalents and marketable securities $1.5B, supporting three imminent launches and indication expansion
- Three Priority Review FDA decisions: BBP-418 November 27, 2026, infigratinib February 4, 2027, encaleret May 8, 2027
- Q3 net loss attributable to common stockholders $83.0M, while operating loss narrowed to $11.6M despite launch investments
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other BridgeBio Pharma, Inc. 8-K filings
Get the next BBIO 8-K as it lands
Follow BBIO for push alerts, or ask the research agent what this filing means.